Try our beta test site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (START)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Novartis
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: April 23, 2012
Last updated: October 26, 2016
Last verified: October 2016
Study to evaluate bradycardiac events during first dose observation of fingolimod in MS patients

Condition Intervention Phase
Multiple Sclerosis
Drug: FTY720
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Number of patients with bradyarrhythmic events [ Time Frame: baseline ]
    number of patients with bradyarrhythmia (2nd or 3rd AV block or heart rate below 40 beats per minute) in ECG during first dose observation

Secondary Outcome Measures:
  • Number of patients with other conduction abnormalities in ECG [ Time Frame: baseline ]
    number of patients with conduction abnormalities such as QT prolongation, first degree AV block during treatment initiation

  • Number of patients with cardiac adverse events [ Time Frame: 7 days ]
    occurrence of subsequent cardiac AEs and serious cardiac AEs during study

Estimated Enrollment: 7000
Study Start Date: June 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fingolimod Drug: FTY720


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with relapsing remitting MS with high disease activity despite treatment with a disease modifying therapy (> 1 relapse in the previous year, > 9 hyperintense T2 lesions or > 1 Gd-enhancing lesion or "non-responding" which could be defined as unchanged or increased relapse rate or ongoing severe relapses compared to previous year) or patients with rapidly evolving severe RRMS (e.g. > 2 relapses with disease progression in one year and > 1 Gd-enhancing lesion or with a significant increase in T2 lesions compared to a recent MRI).

Exclusion Criteria:

  • immunocompromised patients
  • active infections
  • pregnant or nursing women, women of childbearing potential unless using 2 reliable forms of contraception

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01585298

Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals

  Show 276 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01585298     History of Changes
Other Study ID Numbers: CFTY720DDE17 
Study First Received: April 23, 2012
Last Updated: October 26, 2016

Keywords provided by Novartis:
Multiple Sclerosis
conduction abnormalities
first dose observation

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Fingolimod Hydrochloride
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on February 23, 2017